{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:49:08Z","timestamp":1787028548904,"version":"build-2736575974"},"reference-count":102,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T00:00:00Z","timestamp":1726185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Cancer Institute of the National Institutes of Health","award":["5R01CA283699-02"],"award-info":[{"award-number":["5R01CA283699-02"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["5R01CA227277-05"],"award-info":[{"award-number":["5R01CA227277-05"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The clinical outcome of patients with muscle-invasive bladder cancer (MIBC) is poor despite the approval of neoadjuvant chemotherapy or immunotherapy to improve overall survival after cystectomy. MIBC subtypes, immune, transcriptome, metabolomic signatures, and mutation burden have the potential to predict treatment response but none have been incorporated into clinical practice, as tumor heterogeneity and lineage plasticity influence their efficacy. Using the PRISMA statement, we conducted a systematic review of the literature, involving 135 studies published within the last five years, to identify studies reporting on the prognostic value of protein-based biomarkers for response to neoadjuvant therapy in patients with MIBC. The studies were grouped based on biomarkers related to molecular subtypes, cancer stem cell, actin-cytoskeleton, epithelial\u2013mesenchymal transition, apoptosis, and tumor-infiltrating immune cells. These studies show the potential of protein-based biomarkers, especially in the spatial context, to reduce the influence of tumor heterogeneity on a biomarker\u2019s prognostic capability. Nevertheless, currently, there is little consensus on the methodology, reagents, and the scoring systems to allow reliable assessment of the biomarkers of interest. Furthermore, the small sample size of several studies necessitates the validation of potential prognostic biomarkers in larger multicenter cohorts before their use for individualizing neoadjuvant therapy regimens for patients with MIBC.<\/jats:p>","DOI":"10.3390\/ijms25189899","type":"journal-article","created":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T07:30:35Z","timestamp":1726212635000},"page":"9899","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Protein-Based Predictive Biomarkers to Personalize Neoadjuvant Therapy for Bladder Cancer\u2014A Systematic Review of the Current Status"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5071-1025","authenticated-orcid":false,"given":"Stacy","family":"Bedore","sequence":"first","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, 1410 Laney Walker Blvd., Augusta, GA 30912, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"van der Eerden","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, 1410 Laney Walker Blvd., Augusta, GA 30912, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7595-5795","authenticated-orcid":false,"given":"Faizan","family":"Boghani","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, 1410 Laney Walker Blvd., Augusta, GA 30912, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saloni J.","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, 1410 Laney Walker Blvd., Augusta, GA 30912, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer","family":"Yassin","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, 1410 Laney Walker Blvd., Augusta, GA 30912, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina","family":"Aguilar","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, 1410 Laney Walker Blvd., Augusta, GA 30912, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinata B.","family":"Lokeshwar","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, 1410 Laney Walker Blvd., Augusta, GA 30912, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Contieri, R., Martini, A., Mertens, L.S., Giannatempo, P., Hurle, R., Witjes, J.A., Ribal, M.J., van Rhijn, B.W., and Malavaud, B. (2024). The Financial Burden of Guideline-recommended Cancer Medications for Metastatic Urothelial Carcinoma. Eur. Urol. Focus., in press.","DOI":"10.1016\/j.euf.2023.12.002"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.clgc.2024.01.001","article-title":"Management of Metastatic Urothelial Carcinoma in Emerging Markets (EM): An Expert Opinion","volume":"22","author":"Soares","year":"2024","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.euo.2018.07.006","article-title":"Systematic Review of Factors Associated with the Utilization of Radical Cystectomy for Bladder Cancer","volume":"2","author":"Williams","year":"2019","journal-title":"Eur. Urol. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Lokeshwar, S.D., Lopez, M., Sarcan, S., Aguilar, K., Morera, D.S., Shaheen, D.M., Lokeshwar, B.L., and Lokeshwar, V.B. (2022). Molecular Oncology of Bladder Cancer from Inception to Modern Perspective. Cancers, 14.","DOI":"10.3390\/cancers14112578"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.urolonc.2023.04.003","article-title":"The efficacy and safety outcomes of lower dose BCG compared to intravesical chemotherapy in non-muscle-invasive bladder cancer: A network meta-analysis","volume":"41","author":"Kawada","year":"2023","journal-title":"Urol. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.euf.2022.12.003","article-title":"A Systematic Review and Meta-analysis of Chemoablation for Non-muscle-invasive Bladder Cancer","volume":"9","author":"Yanagisawa","year":"2023","journal-title":"Eur. Urol. Focus."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","article-title":"European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines","volume":"85","author":"Carrion","year":"2024","journal-title":"Eur. Urol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Hamid, A., Ridwan, F.R., Parikesit, D., Widia, F., Mochtar, C.A., and Umbas, R. (2020). Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients. BMC Urol., 20.","DOI":"10.1186\/s12894-020-00733-z"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/MOU.0000000000001107","article-title":"Recent developments in perioperative combination therapy in muscle-invasive bladder cancer","volume":"33","author":"Mellema","year":"2023","journal-title":"Curr. Opin. Urol."},{"key":"ref_11","first-page":"e076743","article-title":"Advances in diagnosis and treatment of bladder cancer","volume":"384","author":"Cookson","year":"2024","journal-title":"BMJ"},{"key":"ref_12","first-page":"8493519","article-title":"Neoadjuvant Chemotherapy for Different Stages of Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-analysis","volume":"2022","author":"Liu","year":"2022","journal-title":"Dis. Markers"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Kang, D.H., Cho, K.S., Moon, Y.J., Chung, D.Y., Jung, H.D., and Lee, J.Y. (2022). Effect of neoadjuvant chemotherapy on overall survival of patients with T2-4aN0M0 bladder cancer: A systematic review and meta-analysis according to EAU COVID-19 recommendation. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0267410"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"103795","DOI":"10.1016\/j.critrevonc.2022.103795","article-title":"Neoadjuvant therapy for muscle-invasive bladder cancer: Current clinical scenario, future perspectives, and unsolved questions","volume":"178","author":"Pardo","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Rani, B., Ignatz-Hoover, J.J., Rana, P.S., and Driscoll, J.J. (2023). Current and Emerging Strategies to Treat Urothelial Carcinoma. Cancers, 15.","DOI":"10.20944\/preprints202308.0688.v1"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Boydell, E., Sandoval, J.L., Michielin, O., Obeid, M., Addeo, A., and Friedlaender, A. (2023). Neoadjuvant Immunotherapy: A Promising New Standard of Care. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241411849"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.urolonc.2023.10.004","article-title":"Optimizing outcomes for high-risk, non-muscle-invasive bladder cancer: The evolving role of PD-(L)1 inhibition","volume":"41","author":"Bedke","year":"2023","journal-title":"Urol. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.eururo.2021.09.026","article-title":"The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma","volume":"81","author":"Cathomas","year":"2022","journal-title":"Eur. Urol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Ogbuji, V., Paster, I.C., Recio-Boiles, A., Carew, J.S., Nawrocki, S.T., and Chipollini, J. (2023). Current Landscape of Immune Checkpoint Inhibitors for Metastatic Urothelial Carcinoma: Is There a Role for Additional T-Cell Blockade?. Cancers, 16.","DOI":"10.3390\/cancers16010131"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/s41585-023-00847-7","article-title":"Molecular profile of bladder cancer progression to clinically aggressive subtypes","volume":"21","author":"Guo","year":"2024","journal-title":"Nat. Rev. Urol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/PAP.0000000000000430","article-title":"Molecular Subtypes of Bladder Cancer: Component Signatures and Potential Value in Clinical Decision-making","volume":"31","author":"Warrick","year":"2024","journal-title":"Adv. Anat. Pathol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/JU.0000000000000351","article-title":"Clinical parameters outperform molecular subtypes for predicting outcome in bladder cancer: Results from multiple cohorts, including TCGA","volume":"203","author":"Morera","year":"2020","journal-title":"J. Urol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","article-title":"Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): A multicentre, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Galsky","year":"2020","journal-title":"Lancet"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/PAP.0000000000000383","article-title":"Immunotherapy in Genitourinary Cancers: Role of Surgical Pathologist for Detection of Immunooncologic Predictive Factors","volume":"30","author":"Bahlinger","year":"2023","journal-title":"Adv. Anat. Pathol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.eururo.2019.10.026","article-title":"Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies","volume":"77","author":"Necchi","year":"2020","journal-title":"Eur. Urol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1200\/JCO.18.01148","article-title":"Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study","volume":"36","author":"Necchi","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1158\/1078-0432.CCR-22-2158","article-title":"Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial","volume":"28","author":"Basile","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","article-title":"Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): A randomised, open-label, phase 3 trial","volume":"22","author":"Powles","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ajur.2022.11.005","article-title":"Metabolomics for the diagnosis of bladder cancer: A systematic review","volume":"11","author":"Korkes","year":"2024","journal-title":"Asian J. Urol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Pereira, F., Domingues, M.R., Vitorino, R., Guerra, I.M.S., Santos, L.L., Ferreira, J.A., and Ferreira, R. (2024). Unmasking the Metabolite Signature of Bladder Cancer: A Systematic Review. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25063347"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"J. Clin. Epidemiol."},{"key":"ref_32","first-page":"57","article-title":"Systematic reviews and meta-analyses","volume":"20","author":"Uman","year":"2011","journal-title":"J. Can. Acad. Child. Adolesc. Psychiatry"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13000-023-01295-y","article-title":"Immunohistochemical based molecular subtypes of muscle-invasive bladder cancer: Association with HER2 and EGFR alterations, neoadjuvant chemotherapy response and survival","volume":"18","author":"Helal","year":"2023","journal-title":"Diagn. Pathol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"424","DOI":"10.23736\/S2724-6051.21.04592-4","article-title":"Potential utility of a 4-marker immunohistochemistry panel to predict response to cisplatin-based neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: A single-center preliminary experience","volume":"73","author":"Morselli","year":"2021","journal-title":"Minerva Urol. Nephrol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00428-022-03346-z","article-title":"Uroplakin II as a single marker for luminal versus basal molecular subtypes in muscle invasive urothelial carcinoma","volume":"481","author":"Pryma","year":"2022","journal-title":"Virchows Arch."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"274","DOI":"10.4111\/icu.20200425","article-title":"Association of immunohistochemical markers of tumor subtype with response to neoadjuvant chemotherapy and survival in patients with muscle-invasive bladder cancer","volume":"62","author":"Razzaghdoust","year":"2021","journal-title":"Investig. Clin. Urol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.eururo.2021.10.035","article-title":"Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes","volume":"81","author":"Abrahamsson","year":"2022","journal-title":"Eur. Urol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.euf.2023.03.012","article-title":"Intratumoral Heterogeneity of Molecular Subtypes in Muscle-invasive Bladder Cancer-An Extensive Multiregional Immunohistochemical Analysis","volume":"9","author":"Schallenberg","year":"2023","journal-title":"Eur. Urol. Focus."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Blomqvist, M., Koskinen, I., L\u00f6yttyniemi, E., Mirtti, T., Bostr\u00f6m, P.J., and Taimen, P. (2021). Prognostic and predictive value of ALDH1, SOX2 and SSEA-4 in bladder cancer. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-93245-1"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Hensley, P.J., Kyprianou, N., Purdom, M.S., He, D., DiCarlo, V., Wang, C., and James, A.C. (2019). Predictive Value of Phenotypic Signatures of Bladder Cancer Response to Cisplatin-Based Neoadjuvant Chemotherapy, Elsevier.","DOI":"10.1016\/j.urolonc.2019.06.020"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/21681805.2019.1575467","article-title":"Is Bcl-2 a predictive marker of neoadjuvant chemotherapy response in patients with urothelial bladder cancer undergoing radical cystectomy?","volume":"53","author":"Turker","year":"2019","journal-title":"Scand. J. Urol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.trsl.2021.03.013","article-title":"Combination of biomarkers for neoadjuvant systemic chemotherapy before cystectomy in patients with urinary bladder cancer","volume":"235","author":"Wernroth","year":"2021","journal-title":"Transl. Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/cas.15207","article-title":"Prognostic impact of Schlafen 11 in bladder cancer patients treated with platinum-based chemotherapy","volume":"113","author":"Taniyama","year":"2022","journal-title":"Cancer Sci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e1644108","DOI":"10.1080\/2162402X.2019.1644108","article-title":"Clinical impact of T cells, B cells and the PD-1\/PD-L1 pathway in muscle invasive bladder cancer: A comparative study of transurethral resection and cystectomy specimens","volume":"8","author":"Wahlin","year":"2019","journal-title":"Oncoimmunology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.eururo.2023.11.008","article-title":"Spatial Relationships in the Tumor Microenvironment Demonstrate Association with Pathologic Response to Neoadjuvant Chemoimmunotherapy in Muscle-invasive Bladder Cancer","volume":"85","author":"Beckabir","year":"2024","journal-title":"Eur. Urol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Myint, Z.W., Chahine, Z., Jayswal, R., Bachert, E., McDonald, R.J., Strup, S.E., James, A.C., Hensley, P.J., and Allison, D.B. (2023). Association of CD47 Expression with Clinicopathologic Characteristics and Survival Outcomes in Muscle Invasive Bladder Cancer. J. Pers. Med., 13.","DOI":"10.3390\/jpm13060885"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nrurol.2014.129","article-title":"Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer","volume":"11","author":"Choi","year":"2014","journal-title":"Nat. Rev. Urol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A Consensus Molecular Classification of Muscle-invasive Bladder Cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur. Urol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.eururo.2017.03.030","article-title":"Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy","volume":"72","author":"Seiler","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","article-title":"Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy","volume":"25","author":"Choi","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e443","DOI":"10.1016\/j.clgc.2019.12.003","article-title":"HER2 Status in Molecular Subtypes of Urothelial Carcinoma of the Renal Pelvis and Ureter","volume":"18","author":"Yorozu","year":"2020","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s12253-012-9564-2","article-title":"HER2 status of gastric carcinoma and corresponding lymph node metastasis","volume":"19","author":"Pagni","year":"2013","journal-title":"Pathol. Oncol. Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/1878-0261.12155","article-title":"Emerging functions of the EGFR in cancer","volume":"12","author":"Sigismund","year":"2018","journal-title":"Mol. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"48905","DOI":"10.18632\/oncotarget.16554","article-title":"HER2 and EGFR amplification and expression in urothelial carcinoma occurs in distinct biological and molecular contexts","volume":"8","author":"Eriksson","year":"2017","journal-title":"Oncotarget"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/path.6062","article-title":"The Lund taxonomy for bladder cancer classification\u2014From gene expression clustering to cancer cell molecular phenotypes, and back again","volume":"259","author":"Bernardo","year":"2023","journal-title":"J. Pathol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.humpath.2014.09.007","article-title":"Utility of uroplakin II expression as a marker of urothelial carcinoma","volume":"46","author":"Tian","year":"2015","journal-title":"Hum. Pathol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/bjc.2017.171","article-title":"Tumour heterogeneity poses a significant challenge to cancer biomarker research","volume":"117","author":"Cyll","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"5431","DOI":"10.1038\/s41467-021-25787-x","article-title":"Multi-region exome sequencing reveals the intratumoral heterogeneity of surgically resected small cell lung cancer","volume":"12","author":"Zhou","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/s41379-018-0096-5","article-title":"Discordant molecular subtype classification in the basal-squamous subtype of bladder tumors and matched lymph-node metastases","volume":"31","author":"Eriksson","year":"2018","journal-title":"Mod. Pathol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/path.5813","article-title":"Multilayer spectrum of intratumoral heterogeneity in basal bladder cancer","volume":"256","author":"Sirab","year":"2022","journal-title":"J. Pathol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3233\/BLC-180176","article-title":"Low frequency of intratumor heterogeneity in bladder cancer tissue microarrays","volume":"4","author":"Jakobsson","year":"2018","journal-title":"Bladder Cancer"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/nrc3597","article-title":"Unravelling cancer stem cell potential","volume":"13","author":"Beck","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"470","DOI":"10.3109\/07357907.2014.958231","article-title":"The cancer stem cell hypothesis: A guide to potential molecular targets","volume":"32","author":"Allegra","year":"2014","journal-title":"Cancer Investig."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/(SICI)1520-6408(1999)25:4<353::AID-DVG9>3.0.CO;2-G","article-title":"Distinct functions for Aldh1 and Raldh2 in the control of ligand production for embryonic retinoid signaling pathways","volume":"25","author":"Haselbeck","year":"1999","journal-title":"Dev. Genet."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1158\/0008-5472.CAN-08-4418","article-title":"Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis","volume":"69","author":"Huang","year":"2009","journal-title":"Cancer Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.7314\/APJCP.2014.15.5.2013","article-title":"ALDH1 in combination with CD44 as putative cancer stem cell markers are correlated with poor prognosis in urothelial carcinoma of the urinary bladder","volume":"15","author":"Keymoosi","year":"2014","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1158\/1055-9965.EPI-09-0865","article-title":"Aldehyde dehydrogenase 1 A1-positive cell population is enriched in tumor-initiating cells and associated with progression of bladder cancer","volume":"19","author":"Su","year":"2010","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_68","first-page":"4195","article-title":"Relation of stem cell markers ALDH1 and CD44 with clinicopathological factors in urothelial carcinomas of urinary bladder","volume":"8","author":"Senol","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.stem.2012.12.007","article-title":"The sox family of transcription factors: Versatile regulators of stem and progenitor cell fate","volume":"12","author":"Sarkar","year":"2013","journal-title":"Cell Stem Cell"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.cell.2006.07.024","article-title":"Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors","volume":"126","author":"Takahashi","year":"2006","journal-title":"Cell"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.stem.2011.09.001","article-title":"Sox2(+) adult stem and progenitor cells are important for tissue regeneration and survival of mice","volume":"9","author":"Arnold","year":"2011","journal-title":"Cell Stem Cell"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Lundberg, I.V., L\u00f6fgren Burstr\u00f6m, A., Edin, S., Ekl\u00f6f, V., \u00d6berg, \u00c5., Stenling, R., Palmqvist, R., and Wikberg, M.L. (2014). SOX2 expression is regulated by BRAF and contributes to poor patient prognosis in colorectal cancer. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0101957"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1097\/PAS.0b013e3181e5e024","article-title":"Sox2 protein expression is an independent poor prognostic indicator in stage I lung adenocarcinoma","volume":"34","author":"Sholl","year":"2010","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"12372","DOI":"10.18632\/oncotarget.6029","article-title":"SOX2 boosts major tumor progression genes in prostate cancer and is a functional biomarker of lymph node metastasis","volume":"7","author":"Russo","year":"2016","journal-title":"Oncotarget"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s12032-012-0445-z","article-title":"Predictive value of Sox2 expression in transurethral resection specimens in patients with T1 bladder cancer","volume":"30","author":"Ruan","year":"2013","journal-title":"Med. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s10719-019-09882-2","article-title":"Stage-specific embryonic antigen-4 is a histological marker reflecting the malignant behavior of prostate cancer","volume":"36","author":"Nakamura","year":"2019","journal-title":"Glycoconj. J."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/B978-0-12-394311-8.00014-5","article-title":"Cadherins and epithelial-to-mesenchymal transition","volume":"116","author":"Gheldof","year":"2013","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Lin, W.H., Cooper, L.M., and Anastasiadis, P.Z. (2023). Cadherins and catenins in cancer: Connecting cancer pathways and tumor microenvironment. Front. Cell Dev. Biol., 11.","DOI":"10.3389\/fcell.2023.1137013"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Dev, A., Vachher, M., and Prasad, C.P. (2023). beta-catenin inhibitors in cancer therapeutics: Intricacies and way forward. Bioengineered, 14.","DOI":"10.1080\/21655979.2023.2251696"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/sj.bjc.6601095","article-title":"Role of Bcl-2 as a prognostic factor for survival in lung cancer: A systematic review of the literature with meta-analysis","volume":"89","author":"Martin","year":"2003","journal-title":"Br. J. Cancer"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10549-015-3305-7","article-title":"Bcl-2 is a highly significant prognostic marker of hormone-receptor-positive, human epidermal growth factor receptor-2-negative breast cancer","volume":"150","author":"Seong","year":"2015","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"6116","DOI":"10.1158\/1078-0432.CCR-06-0147","article-title":"Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy","volume":"12","author":"Yoshino","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1046\/j.1464-410x.2000.00612.x","article-title":"Bcl-2 expression identifies patients with advanced bladder cancer treated by radiotherapy who benefit from neoadjuvant chemotherapy","volume":"85","author":"Cooke","year":"2000","journal-title":"BJU Int."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Kiss, B., Skuginna, V., Fleischmann, A., Bell, R.H., Collins, C., Thalmann, G.N., and Seiler, R. (2015). Bcl-2 Predicts Response to Neoadjuvant Chemotherapy and Is Overexpressed in Lymph Node Metastases of Urothelial Cancer of the Bladder, Elsevier.","DOI":"10.1016\/j.urolonc.2014.12.005"},{"key":"ref_85","first-page":"888","article-title":"EMMPRIN (CD147), an inducer of matrix metalloproteinase synthesis, also binds interstitial collagenase to the tumor cell surface","volume":"60","author":"Guo","year":"2000","journal-title":"Cancer Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"jcs223826","DOI":"10.1242\/jcs.223826","article-title":"Survivin at a glance","volume":"132","author":"Wheatley","year":"2019","journal-title":"J. Cell Sci."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1158\/1078-0432.CCR-07-0109","article-title":"Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer","volume":"13","author":"Als","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1002\/cncr.28643","article-title":"Choline phosphate cytidylyltransferase-\u03b1 is a novel antigen detected by the anti-ERCC1 antibody 8F1 with biomarker value in patients with lung and head and neck squamous cell carcinomas","volume":"120","author":"Vaezi","year":"2014","journal-title":"Cancer"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1080\/21681805.2018.1439527","article-title":"Choline-phosphate cytidylyltransferase-\u03b1 as a possible predictor of survival and response to cisplatin neoadjuvant chemotherapy in urothelial cancer of the bladder","volume":"52","author":"Hemdan","year":"2018","journal-title":"Scand. J. Urol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1158\/0008-5472.CAN-13-3058","article-title":"Cofilin drives cell-invasive and metastatic responses to TGF-\u03b2 in prostate cancer","volume":"74","author":"Collazo","year":"2014","journal-title":"Cancer Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.2147\/CMAR.S389825","article-title":"Cofilin Acts as a Booster for Progression of Malignant Tumors Represented by Glioma","volume":"14","author":"Lv","year":"2022","journal-title":"Cancer Manag. Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.humpath.2016.06.020","article-title":"Association of epithelial-mesenchymal transition and nuclear cofilin with advanced urothelial cancer","volume":"57","author":"Hensley","year":"2016","journal-title":"Hum. Pathol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: Integrating immunity\u2019s roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Yu, A., Mansure, J.J., Solanki, S., Siemens, D.R., Koti, M., Dias, A.B., Burnier, M.M., Brimo, F., and Kassouf, W. (2018). Presence of lymphocytic infiltrate cytotoxic T lymphocyte CD3+, CD8+, and immunoscore as prognostic marker in patients after radical cystectomy. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0205746"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1158\/2326-6066.CIR-17-0466","article-title":"Urinary bladder cancer tregs suppress MMP2 and potentially regulate invasiveness","volume":"6","author":"Winerdal","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.ccell.2023.02.017","article-title":"B cells in the tumor microenvironment: Multi-faceted organizers, regulators, and effectors of anti-tumor immunity","volume":"41","author":"Laumont","year":"2023","journal-title":"Cancer Cell"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Bardhan, K., Anagnostou, T., and Boussiotis, V.A. (2016). The PD1: PD-L1\/2 pathway from discovery to clinical implementation. Front. Immunol., 7.","DOI":"10.3389\/fimmu.2016.00550"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1200\/JCO.21.01003","article-title":"Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients with Muscle-Invasive Bladder Cancer","volume":"39","author":"Rose","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_99","first-page":"349","article-title":"Relationship between immunohistochemical staining extent of CD47 and histopathologic features of bladder tumor","volume":"70","author":"Olcucuoglu","year":"2017","journal-title":"Cent. Eur. J. Urol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.canep.2015.03.003","article-title":"Aldehyde dehydrogenase 1 (ALDH1) expression is associated with a poor prognosis of bladder cancer","volume":"39","author":"Xu","year":"2015","journal-title":"Cancer Epidemiol."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Hu, R., Tao, T., Yu, L., Ding, Q., Zhu, G., Peng, G., Zheng, S., Yang, L., and Wu, S. (2022). Multi-Omics Characterization of Tumor Microenvironment Heterogeneity and Immunotherapy Resistance Through Cell States\u2013Based Subtyping in Bladder Cancer. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.809588"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1158\/1078-0432.CCR-23-0602","article-title":"Association of Molecular Subtypes with Pathologic Response, PFS, and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer","volume":"30","author":"Lerner","year":"2024","journal-title":"Clin. Cancer Res."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/18\/9899\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:55:38Z","timestamp":1760111738000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/18\/9899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,13]]},"references-count":102,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["ijms25189899"],"URL":"https:\/\/doi.org\/10.3390\/ijms25189899","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,13]]}}}